| ALQGC Stock | | | EUR 0.07 0 1.77% |
President
Mr. JeanPhilippe Milon is Vice President Operations, Director of Quantum Genomics SA. He previously served as Chief Development Officer of the Company. He is a Healthcare Executive with over twenty five years of commercial experience in Sales and Marketing roles in Pharmaceuticals, Consumer Care and Medical Technologies. He spent 20 years with Bayer Healthcare in Belgium, France and Germany and was Member of the Executive Committee as Senior Vice President Global Licensing and MA. He has also years of experience in cardiovascular diseases, mainly Hypertension, Angina Pectoris, Coronary Heart Disease, Cardiac Insufficiency, Acute Coronary Syndrom and Stroke Prevention in Atrial Fibrillation. He is a Pharmacist Doctor and holds an MBA. since 2019.
| Age | 63 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 33 1 85 34 77 70 |
| Web | https://www.quantum-genomics.com |
Quantum Genomics Management Efficiency
The company has return on total asset
(ROA) of
(0.4751) % which means that it has lost $0.4751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.2274) %, meaning that it generated substantial loss on money invested by shareholders. Quantum Genomics' management efficiency ratios could be used to measure how well Quantum Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Quantum Genomics SA has accumulated 283.69
K in total debt. Quantum Genomics has a current ratio of 3.29, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Quantum Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Quantum Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quantum Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quantum to invest in growth at high rates of return. When we think about Quantum Genomics' use of debt, we should always consider it together with cash and equity.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people. Quantum Genomics SA (ALQGC) is traded on Euronext Paris in France and employs 8 people.
Management Performance
Quantum Genomics Leadership Team
Elected by the shareholders, the Quantum Genomics' board of directors comprises two types of representatives: Quantum Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quantum. The board's role is to monitor Quantum Genomics' management team and ensure that shareholders' interests are well served. Quantum Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quantum Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Quantum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quantum Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to
measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to
predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.